Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
The Doobie Brothers are an American rock band formed in San Jose, California, in 1970. Known for their flexibility in performing across numerous genres and their vocal harmonies, the band has been active for over five decades, with their greatest success taking place in the 1970s. The group's current lineup consists of founding members Tom Johnston (guitars, keyboards, harmonica, vocals) and Patrick Simmons (guitars, banjo, recorder, vocals), alongside Michael McDonald (keyboards, synthesizers, mandolin, vocals) and John McFee (guitars, pedal steel guitar, mandolin, banjo, violin, cello, harmonica, vocals), and touring musicians including John Cowan (bass, vocals), Marc Russo (saxophones), Ed Toth (drums), and Marc Quiñones (percussion, backing vocals). Long-serving former members include guitarist Jeff "Skunk" Baxter, bassist Tiran Porter, and drummers John Hartman, Michael Hossack, and Keith Knudsen. Johnston provided the lead vocals from 1970 to 1975, when they featured a mainstream rock sound with elements of folk, country and R&B. McDonald joined the band in 1975 as a keyboardist and additional lead vocalist, to give some relief to Johnston, who was suffering health problems at the time. McDonald's interest in soul music introduced a new sound to the band. Johnston, Simmons, Porter, and McDonald performed together as lead vocalists for one album, Takin' It to the Streets, before Johnston left in 1977.
In 1660, German scientist Otto von Guericke studied static electricity by building a device comprising a large, rotating sulfur globe, now regarded as the first electrostatic generator. Sulfur appeared in the 1718 "affinity table" of the French chemist Étienne-François Geoffroy, a document that would become influential in chemistry works of the 18th century. Also present in that table was the so-called "Sulfur Principle": at the time, many chemists were convinced that sulfur was not a standalone element but instead contained multiple substances, including a distinct flammable one. This was supported by the phlogiston theory of combustion, which had emerged few decades prior; Geoffroy would later consider the sulfurous principle in his table to be phlogiston. Widely accepted for a century, phlogiston theory was debunked by the work of Antoine Lavoisier on combustion and oxygen. Antoine Lavoisier used sulfur in his combustion experiments, writing of some of these in 1777. In his 1789 Traité Élémentaire de Chimie, considered to be the first modern chemistry textbook, Lavoisier placed sulfur as its own chemical element in a "table of simple substances".
Early on the morning of September 11, 2001, nineteen hijackers took control of four commercial airliners (two Boeing 757s and two Boeing 767s). Large planes with long flights were selected for hijacking because they would have more fuel. Nobody on the planes survived.
==== Agrochemicals ==== Agrochemical companies are the second largest users of fine chemicals. Most products have a "pharmaceutical heritage". As a consequence of an intensive M&A activity (Mergers and Acquisitions) over the past 10–20 years, the industry now is more consolidated than the pharmaceutical industry. The top 10 companies, led by Syngenta, Switzerland; Bayer Cropsciences, Germany: Monsanto, USA; BASF Crop Protection, Germany, and Dow Agrosciences, USA have a share of almost 95% of the total 2,000,000 tons / $48.5 billion pesticide output in 2010. Since the 1990s, the R&D effort has been focused mainly on gene modified (GM) seeds. At both Monsanto and DuPont's seed subsidiary, Pioneer Hi-Bred, the GM seed businesses already account for more than 50% of total sales. 100 new LMW agrochemicals were launched between 2000–2009. However, only 8 products achieved sales in excess of $100 million per year. Generics play a bigger role in the agro than in the pharma industry. They represent some 70% of the global market. China National Chemical Corp is the world's largest supplier of generic farm chemicals. Mahkteshim Agan, Israel, and Cheminova, Denmark, rank second and third. Apart from these multibillion-dollar companies, there are hundreds of smaller firms with sales of less than $50 million per year, mainly in India and China. The incidence of the cost of the active ingredient is about 33%, much higher than in drugs.
Sources: en.wikipedia.org
Livestock farming is one of the top contributors to deforestation, land degradation, water pollution and desertification. Among other reasons, this has led to the new promising technology of meat bioprinting. One alternative to livestock farming is cultured meat, also known as lab-grown meat. Cultured meat is produced by taking a small biopsy from animals, extracting the myosatellite cells and adding growth serum to multiply the cells. The resulting product is then used as a material for bioprinting meat. The post-processing phase, among other steps, includes adding flavour, vitamins and iron to the product. Yet another alternative is printing a meat analogue. Novameat, a Spanish startup has been able to print a plant-based steak and mimic the texture and appearance of real meat. In 2023, Austrian food tech company Revo Foods launched a 3D printed salmon filet alternative based on mycoprotein in Supermarkets of German REWE Group, which became the first 3D printed meat/seafood alternative available in supermarkets worldwide, marking an important milestone towards increased availability of 3D printed food items.
==== MeSH D12.125.067 – amino acids, acidic ==== MeSH D12.125.067.500 – aspartic acid MeSH D12.125.067.500.150 – d-aspartic acid MeSH D12.125.067.500.275 – isoaspartic acid MeSH D12.125.067.500.400 – n-methylaspartate MeSH D12.125.067.500.700 – potassium magnesium aspartate MeSH D12.125.067.750 – glutamic acid MeSH D12.125.067.750.150 – 1-carboxyglutamic acid MeSH D12.125.067.750.400 – glutamates MeSH D12.125.067.750.400.700 – polyglutamic acid MeSH D12.125.067.750.400.800 – sodium glutamate MeSH D12.125.067.750.700 – pyrrolidonecarboxylic acid
Chuvash erythrocytosis or Chuvash polycythemia is an autosomal recessive form of erythrocytosis endemic in patients from the Chuvash Republic in Russia. Chuvash erythrocytosis is associated with homozygosity for a C598T mutation in the von Hippel–Lindau gene (VHL), which is needed for the destruction of hypoxia-inducible factors in the presence of oxygen. Clusters of patients with Chuvash erythrocytosis have been found in other populations, such as on the Italian island of Ischia, located in the Bay of Naples. Patients with Chuvash erythrocytosis experience a significantly elevated risk of events. PHD2 erythrocytosis: Heterozygosity for loss-of-function mutations of the PHD2 gene are associated with autosomal dominant erythrocytosis and increased hypoxia-inducible factors activity. HIF2α erythrocytosis: Gain-of-function mutations in HIF2α are associated with autosomal dominant erythrocytosis and pulmonary hypertension.
Like leptin, observations in both humans and animal models have shown that adiponectin is relevant to insulin sensitivity and energy homeostasis. In contrast, the relationship between resistin and adiposity is not consistent between rodent models and human subjects (See Peter Arner, 2005: "Resistin: yet another adipokine tells us that men are not mice"); hence, the notion of resistin as a genuine adipose-derived hormone remains questionable.
=== Road salt === When plants are exposed to increasing concentrations of road salt, the plant cells become dysfunctional and undergo apoptosis, leading to inhibited growth. Inositol pretreatment could reduce these effects.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.